After consistently failing to meet investor expectations, Novo Nordisk touted a safety profile for CagriSema in line with the ...

Novo Nordisk's hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt after a series of trial results have left investors feeling unsatisfied.

Despite hitting its primary endpoints, patients on CagriSema achieved a weight loss of 22.7% compared to a reduction of 16.1% with semaglutide or 11.8% with cagrilintide after 68 weeks.

Novo Nordisk said CagriSema appeared to have a safe and well-tolerated profile in the latest trial. Photo: mads claus rasmussen/Agence France-Presse/Getty Images ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET. 0422 ET – Novo Nordisk’s shares should reclaim ...

Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data published in December that disappointed investors and wiped $125 billion ...

Novo Nordisk said on Wednesday it plan to file its experimental next-generation obesity drug CagriSema for regulatory approval during the first quarter of next year, slightly later than its ...

Novo reported that, in a late-stage study, a next-generation obesity drug called CagriSema led patients to lose 20% of their weight at 68 weeks when looking at all participants — less than the ...

Novo Nordisk’s shares recovered some ground on Monday after a 27% slump on Friday in response to an underwhelming set of results from a Phase III trial of its new weight-loss drug CagriSema, but ...

BofA analyst Sachin Jain notes that Novo Nordisk (NVO) shares are down about 25%, which is “what we expected in this data scenario,” as CagriSema weight loss data is not as differentiated ...